skip to Main Content
BIO Digital June 8-12, 2020

BIO Digital

Ready to race? Come talk to us at BIO Digital from 8-12th June in our virtual drug discovery pavilion. IRBM are an innovative research organization working across all aspects of drug discovery and early development for different modalities – small molecule, peptides and antibodies.
IRBM Biomarkers Series UK

Biomarkers Series UK

Manuel Daldin, Scientist - High Throughput Biology and Screening and Heidi Kingdon Jones, Global VP Business Development are attending the Biomarker conference in Manchester. Manuel will be presenting on the “development and validation of an assay to detect mutant huntingtin…

JP Morgan Healthcare Confer

Annual JP Morgan Healthcare Conference

Next week, IRBM’s Vice Presidents, Dan Conlon and Michele Luche will be attending the annual JP Morgan Healthcare Conference – the largest healthcare investment symposium in the industry. Get in touch to organise a meeting with Dan and Michele to…

IRBM LinkedIn Events- BioEurope, TIDES, Biotechshowcase.002

TIDES Europe

Our Global VP of Sales and Marketing, Heidi Kingdon Jones, is attending TIDES Europe: Oligonucleotide and Peptide Therapeutics in Amsterdam. Running from November 12-15, the event is Europe's primary forum for thought leaders in this growing field to network and…

Irbm_linkedin_events - Bio Europe

BIO-Europe

From November 11-13, we will be attending BIO-Europe in Hamburg. Our Global VP of Sales and Marketing, Heidi Kingdon Jones, and VP of North American Business Development, Michele Luche, will be on hand to talk about our exceptional drug discovery…

IRBM Events Posts 3.001

ELRIG Drug Discovery 2019

From November 5-6 Heidi Kingdon Jones, our Global VP of Sales and Marketing, will be in Liverpool for ELRIG Drug Discovery 2019. Now in its 13th year, the conference unites those at the forefront of this field to explore the…

IRBM Events Posts 3.002

CPhI Worldwide 2019

We will be in Frankfurt from November 5-7 for CPhI Worldwide. Michele Luche, Vice President of Business Development at IRBM, and Romano Di Fabio who is Corporate Director of Small Molecule R&D at Promidis, part of the IRBM group. Michele…

Back To Top